Research ExplorerPublicationsLoss of SPINK1 expression is associated with unfavorable out...

Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy

Standard

Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. / Rink, Michael; Park, Kyung; Volkmer, Björn G; Xylinas, Evanguelos; Hansen, Jens; Cha, Eugene K; Robinson, Brian D; Hautmann, Richard; Küfer, Rainer; Engel, Oliver; Chun, Felix K; Dahlem, Roland; Rubin, Mark A; Shariat, Shahrokh F; Mosquera, Juan Miguel.

In: UROL ONCOL-SEMIN ORI, Vol. 31, No. 8, 01.11.2013, p. 1716-24.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rink, M, Park, K, Volkmer, BG, Xylinas, E, Hansen, J, Cha, EK, Robinson, BD, Hautmann, R, Küfer, R, Engel, O, Chun, FK, Dahlem, R, Rubin, MA, Shariat, SF & Mosquera, JM 2013, 'Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy', UROL ONCOL-SEMIN ORI, vol. 31, no. 8, pp. 1716-24. https://doi.org/10.1016/j.urolonc.2012.06.011

APA

Rink, M., Park, K., Volkmer, B. G., Xylinas, E., Hansen, J., Cha, E. K., Robinson, B. D., Hautmann, R., Küfer, R., Engel, O., Chun, F. K., Dahlem, R., Rubin, M. A., Shariat, S. F., & Mosquera, J. M. (2013). Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. UROL ONCOL-SEMIN ORI, 31(8), 1716-24. https://doi.org/10.1016/j.urolonc.2012.06.011

Vancouver

Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK et al. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. UROL ONCOL-SEMIN ORI. 2013 Nov 1;31(8):1716-24. https://doi.org/10.1016/j.urolonc.2012.06.011

Bibtex

@article{cdacaa10e0bc4cfba7d9fd0332eeaca2,
title = "Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy",
abstract = "BACKGROUND: We assessed the association of serine protease inhibitor Kazal type I (SPINK1) expression with clinicopathologic outcomes in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).MATERIALS AND METHODS: Tissue microarrays comprising 438 consecutive UCB patients treated with RC between 1988 and 2003 and 62 cases of normal urothelium controls were evaluated for SPINK1 protein expression by immunohistochemistry (IHC). Semiquantitative evaluation was performed by 2 pathologists blinded to clinical outcomes (loss of expression: <50% cells or intensity 0-2).RESULTS: In normal urothelium, SPINK1 expression was noted in umbrella cells of 32 of 62 controls (52%); 254 RC patients (57.9%) exhibited loss of SPINK1 expression. Loss of SPINK1 expression was significantly associated with higher pathologic stages (P = 0.002) and presence of lymph node metastasis (P = 0.04). At a median follow-up of 130 months (IQR: 98.4), loss of SPINK1 expression was associated with an increased risk of disease recurrence (P = 0.02) and cancer-specific mortality (P = 0.03). On multivariable analysis that adjusted for the effects of standard clinicopathologic parameters, SPINK1 was not an independent predictor of disease recurrence (P = 0.09) or cancer-specific mortality (P = 0.12).CONCLUSIONS: Over half of UCB patients treated with RC exhibit loss of SPINK1 expression. Loss of SPINK1 correlates with features of biologically aggressive UCB. Although SPINK1 expression did not have independent prognostic value in RC patients, it may serve as a biomarker for tumor staging and may be useful as an adjunct in clinical decision-making.",
author = "Michael Rink and Kyung Park and Volkmer, {Bj{\"o}rn G} and Evanguelos Xylinas and Jens Hansen and Cha, {Eugene K} and Robinson, {Brian D} and Richard Hautmann and Rainer K{\"u}fer and Oliver Engel and Chun, {Felix K} and Roland Dahlem and Rubin, {Mark A} and Shariat, {Shahrokh F} and Mosquera, {Juan Miguel}",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = nov,
day = "1",
doi = "10.1016/j.urolonc.2012.06.011",
language = "English",
volume = "31",
pages = "1716--24",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy

AU - Rink, Michael

AU - Park, Kyung

AU - Volkmer, Björn G

AU - Xylinas, Evanguelos

AU - Hansen, Jens

AU - Cha, Eugene K

AU - Robinson, Brian D

AU - Hautmann, Richard

AU - Küfer, Rainer

AU - Engel, Oliver

AU - Chun, Felix K

AU - Dahlem, Roland

AU - Rubin, Mark A

AU - Shariat, Shahrokh F

AU - Mosquera, Juan Miguel

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: We assessed the association of serine protease inhibitor Kazal type I (SPINK1) expression with clinicopathologic outcomes in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).MATERIALS AND METHODS: Tissue microarrays comprising 438 consecutive UCB patients treated with RC between 1988 and 2003 and 62 cases of normal urothelium controls were evaluated for SPINK1 protein expression by immunohistochemistry (IHC). Semiquantitative evaluation was performed by 2 pathologists blinded to clinical outcomes (loss of expression: <50% cells or intensity 0-2).RESULTS: In normal urothelium, SPINK1 expression was noted in umbrella cells of 32 of 62 controls (52%); 254 RC patients (57.9%) exhibited loss of SPINK1 expression. Loss of SPINK1 expression was significantly associated with higher pathologic stages (P = 0.002) and presence of lymph node metastasis (P = 0.04). At a median follow-up of 130 months (IQR: 98.4), loss of SPINK1 expression was associated with an increased risk of disease recurrence (P = 0.02) and cancer-specific mortality (P = 0.03). On multivariable analysis that adjusted for the effects of standard clinicopathologic parameters, SPINK1 was not an independent predictor of disease recurrence (P = 0.09) or cancer-specific mortality (P = 0.12).CONCLUSIONS: Over half of UCB patients treated with RC exhibit loss of SPINK1 expression. Loss of SPINK1 correlates with features of biologically aggressive UCB. Although SPINK1 expression did not have independent prognostic value in RC patients, it may serve as a biomarker for tumor staging and may be useful as an adjunct in clinical decision-making.

AB - BACKGROUND: We assessed the association of serine protease inhibitor Kazal type I (SPINK1) expression with clinicopathologic outcomes in urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).MATERIALS AND METHODS: Tissue microarrays comprising 438 consecutive UCB patients treated with RC between 1988 and 2003 and 62 cases of normal urothelium controls were evaluated for SPINK1 protein expression by immunohistochemistry (IHC). Semiquantitative evaluation was performed by 2 pathologists blinded to clinical outcomes (loss of expression: <50% cells or intensity 0-2).RESULTS: In normal urothelium, SPINK1 expression was noted in umbrella cells of 32 of 62 controls (52%); 254 RC patients (57.9%) exhibited loss of SPINK1 expression. Loss of SPINK1 expression was significantly associated with higher pathologic stages (P = 0.002) and presence of lymph node metastasis (P = 0.04). At a median follow-up of 130 months (IQR: 98.4), loss of SPINK1 expression was associated with an increased risk of disease recurrence (P = 0.02) and cancer-specific mortality (P = 0.03). On multivariable analysis that adjusted for the effects of standard clinicopathologic parameters, SPINK1 was not an independent predictor of disease recurrence (P = 0.09) or cancer-specific mortality (P = 0.12).CONCLUSIONS: Over half of UCB patients treated with RC exhibit loss of SPINK1 expression. Loss of SPINK1 correlates with features of biologically aggressive UCB. Although SPINK1 expression did not have independent prognostic value in RC patients, it may serve as a biomarker for tumor staging and may be useful as an adjunct in clinical decision-making.

U2 - 10.1016/j.urolonc.2012.06.011

DO - 10.1016/j.urolonc.2012.06.011

M3 - SCORING: Journal article

C2 - 22944196

VL - 31

SP - 1716

EP - 1724

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 8

ER -